Hluti af safninu Dæmi um fjárfestakynningar · Dæmi um japanskar fjárfestakynningar
M3 H1 FY2026 Earnings Presentation: M3, Inc.'s (エムスリー株式会社) 44-page Japanese-language company presentation (会社説明資料, November 2026), released on TDnet (the Tokyo Stock Exchange timely-disclosure system) together with its second-quarter results for the fiscal year ending March 2027 (FY2026 = April 2026 to March 2027). It covers H1 consolidated and segment results (revenue ¥181,853 million, +6%; operating profit ¥36,335 million, +1%), progress against the H1 forecast, the medical platform growth strategy (pharma marketing support and clinic DX), AI initiatives on m3.com and M3 DigiKar, the overseas segment and its '¥2 billion (20億円) club' businesses, the programmatic M&A strategy, the long-run revenue and profit history with the FY2026 forecast (revenue ¥400,000 million, operating profit ¥80,000 million) and a disclosure on the October 2026 unauthorized access to the 'MR-kun' system.
Notar forsíðu þessarar kynningar sem stílfyrirmynd fyrir glærur úr þínu eigin efni. Eða veldu hvaða síðu sem er hér fyrir neðan og notaðu uppsetningu hennar sem fyrirmynd.
Flýtileiðsögn
Merki
Deila glærunum
M3 H1 FY2026 Earnings Presentation: M3, Inc.'s (エムスリー株式会社) 44-page Japanese-language company presentation (会社説明資料, November 2026), released on TDnet (the Tokyo Stock Exchange timely-disclosure system) together with its second-quarter results for the fiscal year ending March 2027 (FY2026 = April 2026 to March 2027). It covers H1 consolidated and segment results (revenue ¥181,853 million, +6%; operating profit ¥36,335 million, +1%), progress against the H1 forecast, the medical platform growth strategy (pharma marketing support and clinic DX), AI initiatives on m3.com and M3 DigiKar, the overseas segment and its '¥2 billion (20億円) club' businesses, the programmatic M&A strategy, the long-run revenue and profit history with the FY2026 forecast (revenue ¥400,000 million, operating profit ¥80,000 million) and a disclosure on the October 2026 unauthorized access to the 'MR-kun' system.
Ítarleg sýn á hverja glærusíðu, þar á meðal útlit, lykilefni og sjónræna þætti.
Japanese cover reading エムスリー株式会社 (M3, Inc.), 会社説明資料 (Company Presentation) and 2026年11月 (November 2026), with M3's hand-drawn waveform logo; the file was released on TDnet as the Q2 results presentation for the fiscal year ending March 2027.
Centered title stack on white with navy double rules at top and bottom and a copyright footer.
Standard Japanese disclaimer: statements about outlooks, plans and targets are based on information available when the document was prepared and on certain assumptions that may prove inaccurate; third-party information comes from public sources and is not verified; the document is for information only, not a solicitation to invest.
Single block of body text with the company name right-aligned at the bottom.
In ¥ million, H1 FY2025 vs H1 FY2026: revenue 170,885 → 181,853 (+6%); operating profit 35,992 → 36,335 (+1%); profit before tax 36,681 → 36,620 (-0%); interim profit 25,320 → 22,623 (-11%). The footnote says FY2026 includes a one-off tax expense in H1 tied to a dividend from an overseas subsidiary; the takeaway is that Q2 turned to revenue and profit growth.
Four-row results table with navy column headers for the two periods and a blue YoY column; FY2026 column shaded pale yellow; call-out line and footnote below.
Japan segments, H1 FY2025 → H1 FY2026 (¥ million): Medical Platform revenue 51,977 → 54,384 (+5%), profit 17,870 → 18,487 (+3%); Evidence Solutions 12,180 → 11,713 (-4%), profit 2,331 → 1,973 (-15%); Career Solutions 13,175 → 12,686 (-4%), profit 4,343 → 4,438 (+2%); Site Solutions 26,291 → 28,735 (+9%), profit 1,694 → 930 (-45%); Patient Solutions 27,352 → 30,229 (+11%), profit 1,054 → 2,011 (+91%); Emerging Businesses 1,064 → 1,033 (-3%), profit 578 → 304 (-47%). Overseas revenue 41,063 → 45,447 (+11%), profit 8,925 → 9,854 (+10%). Call-outs: pharma-marketing order backlog at end-Q2 up 14% YoY helped by problem-solving proposals and clinic DX still solid; Evidence Solutions backlog ¥36.4 billion (364億円) with Q2 back to growth after high-margin and large projects rolled off in Q1; Career Solutions slow in pharmacist placement after the medical-fee revision but profit up on mix, with sales-force strengthening including AI; Emerging Businesses lower on equity-method income after last year's affiliate share sale; Overseas profit +29% in Q2 on investment timing and mix.
Dense segment table on the left (Japan block with vertical 国内 label, Overseas block below) and five yellow call-out boxes with orange pointer arrows on the right.
Two waterfall bridges from the initial H1 forecast to actual: revenue ¥192.0 billion (1,920億円) forecast → ¥181.9 billion (1,819億円) actual, and operating profit ¥37.0 billion (370億円) → ¥36.3 billion (363億円), with bars for MP, ES, CS, SS, PS, Overseas and Other/adjustments. The takeaway: across H1, Overseas fell furthest short of plan, but its shortfall narrowed in Q2. Individual segment variances are shown only as bar lengths, not as numbers.
Side-by-side horizontal waterfall charts with broken-axis forecast and actual bars, segment labels on the left, takeaway and footnote below.
Agenda of the strategy section in four parts: (1) the Medical Platform today and its growth strategy; (2) creating new value from proprietary data in the AI era; (3) the overseas business today and drivers for medium-term growth; (4) an update on sustained growth through the programmatic M&A strategy.
Four numbered chevron bars arranged along a curved arc, with the waveform logo on the left.
The agenda repeated with item 1, the Medical Platform's current state and future growth strategy, highlighted and items 2–4 greyed out.
Same arc agenda as page 6 with one active item and three greyed items.
Waterfall from ¥34.3 billion (343億円) operating profit in FY2019 to ¥74.7 billion (747億円) in FY2025, excluding one-offs such as impairments and gains on sales, segment steps rounded to ¥0.5 billion: pharma marketing +100, clinic DX +50, WJP (White Jack Project) +15, other MP +25, ES 0, CS +15, SS +35, PS +25, other/adjustments 0, Overseas +140 (all ¥100 million). Consolidated CAGR 14%. Takeaway: besides pharma marketing, other businesses contributed heavily; 75% of the profit increase came from outside pharma marketing, so there are multiple profit engines.
Full-width waterfall chart with navy start and end columns, magenta MP steps, blue Japan-segment steps and a green Overseas step, a large orange trend arrow and a CAGR banner.
Divider titled 医薬品、営業＆マーケティングのDX (digital transformation of pharmaceutical sales and marketing), opening the pharma-marketing sub-section.
Full-width navy band across the middle of a white slide with white bold title.
The FY2019–FY2025 operating profit waterfall (¥34.3 billion to ¥74.7 billion, 14% CAGR) repeated with the pharma-marketing step (+¥10 billion, 100億円) highlighted in pink and all other steps faded.
Same waterfall as page 8 with a pink vertical highlight band over the pharma-marketing column.
M3 estimates of Japan pharma sales spend (TAM): ten years ago about ¥1.5 trillion in MR-related costs (~99%) and about ¥15 billion online (~1%); today about ¥1.15 trillion MR-related (~95%) and about ¥70 billion online (~5%), with total spend down about ¥300 billion; in future MR-related costs of about ¥700–800 billion (~70–80%) and online about ¥200–300 billion (~20–30%) as DX lifts industry sales productivity. M3's role spans (1) internet marketing support, (2) DX support for MR activity and (3) data-driven marketing support across both. Takeaway: M3's involvement goes beyond the internet, aiming to improve productivity across the whole industry.
Three stacked green-and-navy columns (10 years ago / current / future) with red TAM outlines, orange downward arrows showing shrinkage, and a right-hand panel listing M3's three roles with a brace.
FY2025 status of 'problem-solving' (課題解決型) proposals, based on internal management accounting: of 680 target drugs, 75 (11%) received problem-solving proposal programs and 105 (15%) other related programs; these groups made up 37% and 28% of M3's related revenue respectively, and their revenue grew 33% and 8% YoY. Takeaway: M3 scaled up problem-solving proposals from FY2025, and targeted drugs grew 8–33% that year.
Three linked panels: stacked bar of drug counts, stacked bar of revenue mix connected by trapezoid lines, and a horizontal bar chart of growth rates; 'reprinted' badge at top right.
Index with H1 FY2025 = 100: number of orders 152 (about 1.5x) × order value per project 127 (about 1.3x) = total order value 193 (about 1.9x). Takeaway: H1 orders from problem-solving proposals were about 1.9 times the prior-year period.
Three paired bar charts laid out as an equation with large brown × and = symbols between them; multiplier arrows beside each pair.
Balance-scale illustration: in FY2026 Q1, pharma companies' sales-budget cuts (minus) outweighed the start of problem-solving proposals (plus), so the pharma-marketing order backlog was down YoY; in Q2, strong data and AI products and orders from problem-solving proposals (two pluses) outweighed the budget cuts and the backlog turned positive YoY. Takeaway: despite budget pressure at pharma companies, orders are improving.
Two balance-scale graphics (Q1 tilted left, Q2 tilted right) joined by an arrow, with a yellow strip below showing minus turning into plus plus for the YoY backlog.
March 2016 → March 2026 → medium-term target: drugs served (only drugs with ¥30 million+ annual M3 revenue) ~100 → ~250 (about 2x) → ~500 (~2x); revenue per drug ~¥100 million (1億円) → ~¥150 million (1.5億円) (about 2x) → ¥200–300 million (2–3億円) (~2x); illustrative total revenue ¥15–20 billion (150–200億円) → ¥40–50 billion (400–500億円) (2–3x) → ¥100–150 billion (1,000–1,500億円) (2–3x). The 2016 figures include estimates since per-drug tracking began in FY2020. Takeaway: grow both the number of drugs and revenue per drug through higher-value bundled proposals and larger projects.
Three-column timeline table with teal period headers and three rows (drugs, revenue per drug, total) linked by orange multiplier arrows.
Divider titled 医療現場のDX (digital transformation at the point of care), opening the clinic and hospital DX sub-section.
Full-width navy band across the middle of a white slide with white bold title.
The FY2019–FY2025 operating profit waterfall repeated with the clinic-DX (医療現場DX) step of +¥5 billion (50億円) highlighted in pink.
Same waterfall as page 8 with a pink highlight band over the clinic-DX column.
Bar chart of M3 DigiKar (cloud EHR) installed facilities by fiscal year, FY15–FY26, rising steeply to about 10,700 facilities as of FY2026 Q2 (only the latest value is labeled). Call-outs: cumulative installations progressing steadily; cross-selling with Digisma further raises DigiKar's value. Takeaway: overwhelming No. 1 share of the cloud EHR market.
Navy column chart with a curved orange growth arrow on the left; yellow call-out box on the right.
Digisma Shinryo covers the whole patient journey for in-person and online visits: booking, automatic check-in, pre-visit questionnaire, EHR integration, payment and next-visit booking, with a management system for clinics and a smartphone app for patients. App Store screenshot (cited 15 October 2026) shows the M3 Digital Smart patient-ticket app rated 4.6 from 130,000 ratings and ranked #1 in Medical. Takeaway: users give it 4.6 across 130,000 ratings, a new patient experience with top ratings in its category.
Circular workflow diagram on the left around the Digisma logo; centre column with clinic and patient illustrations; right panel with an App Store rating screenshot in a yellow frame; source URL at the bottom.
Index of quarterly users (sum of monthly unique users per quarter, FY2021 Q3 = 1): 1, 44, 173, 479, 1,070, 1,368, 2,067, 2,973, 4,320, 4,741, 5,673, 7,089, 9,437, 10,042, 11,400, 13,201, 17,446, 17,743, 18,739 and 21,177 in FY2026 Q2. Call-outs: spreading fast as clinic infrastructure, with users 1.6x and payment value 1.7x year on year; a video-call function has been added, so it is also growing as online-consultation infrastructure.
Twenty-bar quarterly column chart with value labels and fiscal-year pills on the x-axis; yellow call-out box on the right.
March 2021 → March 2026 → medium-term target: facilities using M3's medical-institution services (DigiKar, Digisma, on-premise EHR, home-care physician support, real-estate-related services, etc.) ~5,500 → ~15,000 (about 3x) → 30,000+ (~2x); revenue per facility ~¥600,000 (60万円) → ~¥1.1 million (110万円) (about 2x) → ¥2–3 million (200–300万円) (2–3x); illustrative total revenue about ¥3 billion (30億円) → about ¥16 billion (160億円) (about 5x) → ¥60–90 billion (600–900億円) (4–6x). Takeaway: support DX across healthcare sites by adding facilities and services.
Three-column timeline table with blue period headers and three rows linked by orange multiplier arrows.
The agenda repeated with item 2, creating new added value from proprietary data in the AI era, highlighted.
Arc agenda with item 2 active and others greyed.
The FY2019–FY2025 operating profit waterfall repeated with the whole Medical Platform bracket (pharma marketing +100, clinic DX +50, WJP +15, other MP +25, in ¥100 million) highlighted in pink, introducing the AI section.
Same waterfall as page 8 with a wide pink band over all four MP steps.
Annotated screenshot of the m3.com home page with orange boxes marking AI-personalized content blocks. Call-outs: M3 already uses AI fully to tailor content to each physician's characteristics; on the m3.com top page, for example, more than 80% of content is AI-personalized.
Large portal screenshot on the left with orange overlay boxes, legend at top right and a yellow call-out bubble pointing at the screenshot; m3.com badge in the header.
Total member time on site, index FY2021 Q4 (before ChatGPT's release) = 100: FY2024 Q4 113 (after three years) and FY2025 Q4 124 (one more year). Takeaway: by using AI fully, physician activity on m3.com is rising at an accelerating pace, so AI progress is a tailwind.
Three-bar column chart with an orange connecting line and curved arrows labeled '3 years' and '1 year' under the axis.
Example screen of 'm3.com AI' (beta) answering a clinical question about starting an SGLT2 inhibitor in an elderly patient with HFrEF and CKD stage G4, with cited m3.com articles alongside. Call-outs: an AI assistant fully built into m3.com from November; answers personalized to each physician's specialty and interests based on profile and behaviour logs; uses m3.com's proprietary content and medical books bought on m3.com. Takeaway: test-released to some members in spring, then launched to all physician members from November.
Chat-interface screenshot with a reference-list sidebar on the left (cut with a wave edge); yellow bullet box on the right; 'example' tag at top left.
Screenshot of the DigiKar AI agent panel (prompts such as summarize the last three months of records, draft findings from the questionnaire, write a referral letter, SOAP entry by voice). Features: voice-input charting, where the agent transcribes, summarizes and organizes consultation conversations; document drafting from charts and test values; and reassurance on security and data handling compared with general-purpose AI. Takeaway: within about two months of launch it was adopted by about 20% of all installed facilities, about 2,000 sites (as of end-September 2026, monthly fee ¥8,800), reducing physicians' workload.
Illustration of a doctor at a monitor with a zoomed-in AI panel joined by red dashed lines; yellow feature box on the right; DigiKar badge in the header.
FY2025 AI return, index with AI-related spend (engineer costs, AI tool fees, medical-AI business costs) = 100: AI impact on operating profit = 1,654, about 17 times. Sources of impact: group-wide value created by an elite AI engineering team, the medical AI platform business, and cost savings through efficiency, including IT support for group companies. Takeaway: dozens of AI projects are already running and the business impact is expected to accelerate.
Two-bar chart (small 100 vs tall 1,654) with an orange up arrow and red '~17x' label; yellow bullet box on the right.
The agenda repeated with item 3, the overseas business today and drivers for medium-term growth, highlighted.
Arc agenda with item 3 active and others greyed.
The FY2019–FY2025 operating profit waterfall repeated with the Overseas step of +¥14 billion (140億円), the largest single contributor, highlighted in green.
Same waterfall as page 8 with a green highlight band over the Overseas column.
Dotted world map with donut charts of M3's physician-member share as of end-June 2026 for the UK, Germany, France and Spain in Europe; China, Korea, India and Japan in Asia; and the US in North America. Exact percentages are not printed; the donuts show high coverage in Japan, Korea, China, France, Spain and the UK, and lower shares in Germany and India. Takeaway: including other regions, more than 7 million physician members, covering 50% of physicians worldwide.
World map in green dots with regional labels and navy/grey donut charts placed on each country.
In ¥ million, H1 FY2025 → H1 FY2026: North America 14,464 → 16,342 (+13%); Europe 17,681 → 19,186 (+9%); APAC/other 8,913 → 9,908 (+11%); total 41,058 → 45,436 (+11%). Notes: in North America uncertainty remains in clinical trials, but other businesses mostly grew; Europe grew led by France; APAC grew led by India and Korea. Takeaway: business progress plus FX lifted revenue in every region, and M3 is speeding up initiatives for the future, including upfront investment.
Two stacked columns with regional segments and red growth-rate labels; right-hand commentary blocks with colored region headings.
FY2025 overseas businesses by annual revenue (excluding the US clinical-trial business and the UK physician-career business): 24 businesses in total, of which 46% have revenue of ¥2 billion (20億円) or more and generate 93% of about ¥90 billion (900億円) combined revenue; operating margin (excluding amortization and impairment) is about 25% for that group vs about 11% for the rest, about 2x. Takeaway: invest small (under ¥1 billion revenue), find the winning approach, then scale investment toward ¥2 billion revenue.
Two stacked 100% columns (business count and revenue) connected by grey lines, plus a horizontal margin bar chart with an orange '~2x' arrow.
March 2021 → March 2026 → medium-term target for '¥2 billion club' businesses: number 6 → 12 (about 2x) → ~20 (~2x); revenue per business ¥5.5 billion (55億円) → ¥7 billion (70億円) (about 1x) → ¥10–12 billion (100–120億円) (~2x); illustrative total overseas revenue including other businesses ¥42 billion (420億円) → ¥87 billion (870億円) (about 2x) → ¥200–250 billion (2,000–2,500億円) (~3x). FX from next year is fixed at USD = ¥150, GBP = ¥200, EUR = ¥180. Takeaway: grow both the number of overseas businesses and revenue per business.
Three-column timeline table with green period headers, a merged row label for the ¥2 billion club and orange multiplier arrows.
The agenda repeated with item 4, an update on sustained growth through the programmatic M&A strategy, highlighted.
Arc agenda with item 4 active and others greyed.
Acquisitions per year (Japan / overseas): FY2022 11 (5 / 6); FY2023 10 (3 / 7); FY2024 15 (9 / 6); FY2025 5 (2 / 3); FY2026 to the Q2 announcement 4 (4 / 0). Footnote lists deals done by listed subsidiaries each year (e.g., FY2026: 1 of the 4 Japan deals). Takeaway: M3 keeps doing about 10 deals a year; the number of deals under review is at the usual pace and the basic strategy is unchanged.
Stacked column chart with navy (Japan) and teal (overseas) segments, grey connector lines between bars and a legend box.
The four-part agenda shown with all items active as a recap before the long-term section: Medical Platform strategy, AI-era value creation, overseas growth drivers and programmatic M&A.
Arc agenda with all four items in active blue.
FY2010 → 2015 → 2020 → 2025: countries 3 → 8 (2.5x) → 11 (3.5x) → 18 (6.0x); business types 6 → 15 (2.5x) → 35 (6.0x) → 41 (7.0x); businesses deployed (type × country) 10 → 24 (2.5x) → 56 (5.5x) → 81 (8.0x); revenue (¥100 million) 146 → 647 (4.5x) → 1,692 (12.0x) → 3,514 (24.0x). Takeaway: to realize growth potential of 10–20 times or more from today, M3 will keep making aggressive upfront investments, including M&A.
Four-row data table overlaid on a faded sepia photo of a construction scene, with arrows between years and multiples in parentheses.
Revenue build by business vintage: FY2010 ¥15 billion (150億円); FY2015 ¥65 billion (~360 from FY2010 businesses, ~290 from FY2011–15 additions); FY2025 ¥351 billion (3,510億円: ~840 / ~1,170 / ~1,500 from FY2016–25 additions); about five years later ~¥800 billion (~8,000億円: ~1,300 / ~2,400 / ~3,000 plus ~1,300 from businesses added from FY2026), all in ¥100 million. Assumptions: CAGR ~10% for FY2010 businesses, ~15% for FY2011–15 and FY2016–25 vintages, and new businesses adding about one-fifth of existing revenue. Takeaway: grow through both new and existing businesses while pushing AI use.
Stacked column chart by vintage with a large orange growth arrow, a legend box on the left and a yellow 'calculation assumptions' column on the right.
Divider titled FY2026 業績見通し (FY2026 earnings outlook), introducing the long-term results history and the full-year forecast.
Full-width navy band across the middle of a white slide with white bold title.
Revenue (¥ million) FY2000 (6 months) to FY2025 with FY2026 estimate: 107, 480, 891, 1,563, 2,276, 3,854, 5,729, 7,475, 8,534, 11,811, 14,646, 19,040, 26,007, 36,759, 51,346, 64,660, 78,143, 94,471, 113,059, 130,973, 169,198, 208,159, 230,818, 238,883, 284,900, 351,363 and 400,000E. Operating profit: -93, 46, 255, 509, 895, 1,683, 2,677, 3,597, 3,990, 4,803, 6,031, 7,648, 9,294, 13,738, 16,061, 20,022, 25,050, 27,486, 30,800, 34,337, 57,972, 64,210 (FY2021 excluding China IPO-related gains; 95,141 including them), 71,983, 64,381, 62,971, 73,547 and 80,000E. Takeaway: aim to expand the business base and deliver growth with a medium- to long-term view.
Two side-by-side column charts (revenue and operating profit) with value labels and a light-blue estimate bar for FY2026; dashed outline marking China IPO-related profit.
Overview: unauthorized access to the MR-kun system was confirmed on 14 October 2026. Impact: leakage of personal information of m3.com members and pharma-company staff was confirmed. Response: the illegitimate access routes identified so far have been contained, and no new data theft from this incident has been found, including in other services. Q&A: m3.com usage has not changed significantly; MR-kun and DigiKar/Digisma run on different systems. Takeaway: M3 will further strengthen information-security and personal-data management to prevent recurrence.
Three labeled rows (overview / impact / response) with dark grey tag cells, then two light-blue Q&A panels and a takeaway line.
Closing logo slide with the waveform mark and the wordmark 'M3, Inc.'.
Centered logo lockup on white with navy top rule and copyright footer.
Defines the abbreviations used in the deck: Medical Platform = MP, Evidence Solutions = ES, Career Solutions = CS, Site Solutions = SS, Patient Solutions = PS.
Two-column definition list (full segment name / abbreviation) separated by dotted rules.
Algengar spurningar um þessa glæru og undirliggjandi kynningarefni.
The original deck is in Japanese. M3, Inc. (エムスリー株式会社) released it on TDnet, the Tokyo Stock Exchange's timely-disclosure system, with its Q2 results for the fiscal year ending March 2027. On TDnet it is called the results presentation (決算説明資料), but the cover says 会社説明資料 (company presentation), November 2026. The page-by-page summary on this page is in English, with key figures translated and the company's own units kept (百万円 = ¥ million, 億円 = ¥100 million).
M3's fiscal year runs from April to March, so FY2026 is April 2026 to March 2027 (the fiscal year ending March 2027). H1, or Q1–Q2, is April to September 2026.
Revenue was ¥181,853 million (+6% YoY) and operating profit ¥36,335 million (+1%). Profit before tax was ¥36,620 million (roughly flat) and interim profit ¥22,623 million (-11%). The drop in interim profit reflects a one-off tax expense linked to a dividend from an overseas subsidiary. The deck says Q2 alone returned to revenue and profit growth.
The results-history slide shows a FY2026 estimate of ¥400,000 million revenue and ¥80,000 million operating profit, up from ¥351,363 million and ¥73,547 million in FY2025. Against the H1 plan, revenue came in at ¥181.9 billion vs ¥192.0 billion forecast and operating profit at ¥36.3 billion vs ¥37.0 billion. Overseas was the biggest shortfall.
Patient Solutions (+11% revenue, +91% profit), Overseas (+11% revenue, +10% profit) and Site Solutions (+9% revenue) grew fastest. Medical Platform grew revenue 5% and profit 3%. Evidence Solutions and Career Solutions revenue fell 4% each. Site Solutions profit fell 45% and Emerging Businesses profit fell 47%.
More than 80% of m3.com home-page content is AI-personalized, and physician time on site rose to an index of 124 in FY2025 Q4 (FY2021 Q4 = 100). The 'm3.com AI' clinical assistant launched to all physician members in November 2026. The DigiKar EHR AI agent reached about 2,000 clinics within two months. M3 puts the FY2025 operating-profit impact of AI at about 17 times its AI spend.
Pharma marketing aims for about 500 drugs at ¥200–300 million each (¥100–150 billion in total). Medical-institution services aim for 30,000+ facilities at ¥2–3 million each (¥60–90 billion). Overseas aims for about 20 businesses with ¥2 billion+ revenue, and total overseas revenue of ¥200–250 billion. A five-year scenario slide shows group revenue reaching about ¥800 billion.
Yes. It is a good reference for a results deck that also tells a long-term growth story. Formats worth reusing include the operating-profit waterfall that is reused to highlight each business, the 'count × revenue per unit = total' growth-target tables, the forecast-vs-actual bridge and the incident-disclosure Q&A page. You can download the PDF free from this page.
Original Japanese PDF released through the Tokyo Stock Exchange timely-disclosure system.
Create Your Own Slides
Turn your ideas into professional presentations in seconds with 2slides AI.
Sæktu innblástur í faglega hönnun, veldu þinn stíl og búðu til glærur með fullkominni textabirtingu. Knúið af Nano Banana—byrjaðu að búa til kynninguna þína núna.
Þinn AI-þjónn fyrir glærur. Sparaðu tíma, skín hraðar með snjallri kynningargerð.
© 2026 2slides. Allur réttur áskilinn.